NCT01607372View on ClinicalTrials.gov

A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Asthma and Rhinitis
Interventions
DRUG

GSK2245035

GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate

DEVICE

Type 1 amber glass bottle

fitted with a metered Valios VP7 pump

OTHER

Placebo

As for GSK2245035 nasal spray solution except for omission of the active ingredient

Trial Locations (1)

M5V 2T3

GSK Investigational Site, Toronto

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

PATH

OTHER

lead

GlaxoSmithKline

INDUSTRY